Comparative Pharmacology
Head-to-head clinical analysis: SELENIUM SULFIDE versus VFEND.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SELENIUM SULFIDE versus VFEND.
SELENIUM SULFIDE vs VFEND
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selenium sulfide is an antifungal and cytostatic agent. It reduces sebum production and inhibits the growth of Malassezia species by interfering with fungal lipid metabolism and cell wall synthesis. The exact molecular mechanism is not fully elucidated.
Inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Topical: 2.5% lotion or shampoo applied to affected area once daily for 7 days; 1% shampoo used once or twice weekly for maintenance.
IV: Loading dose of 6 mg/kg every 12 hours for 2 doses, then 4 mg/kg every 12 hours. Oral: Weight ≥40 kg: Loading dose of 400 mg every 12 hours for 2 doses, then 200 mg every 12 hours; weight <40 kg: Loading dose of 200 mg every 12 hours for 2 doses, then 100 mg every 12 hours.
None Documented
None Documented
Not established; due to negligible systemic absorption, a terminal half-life is not clinically relevant. If absorbed, selenium has a long biological half-life of approximately 65–115 days due to incorporation into selenoproteins.
Terminal half-life is approximately 24 hours (range 12–30 h) in adults. Prolonged in hepatic impairment (Child-Pugh A: 48 h; B: 72 h).
Selenium sulfide is minimally absorbed after topical application. The small absorbed fraction is excreted renally as selenite or selenate, with fecal excretion of unabsorbed drug accounting for >90% of the dose.
Primarily hepatic metabolism; <2% excreted unchanged in urine. Fecal excretion accounts for ~80% of metabolites. Renal excretion of unchanged drug is negligible.
Category A/B
Category C
Antifungal / Antiseborrheic
Antifungal